Full Press Release Details
HELIUS MEDICAL TECHNOLOGIES INVENTORS GRANTED US PATENT NO.
for Providing Non-Invasive Neurorehabilitation of
NEWTOWN, PA July 15, 2015 - Helius Medical Technologies, Inc.
(CSE: HSM; OTCQB: HSDT) ( Helius , or the Company ) announced today that the US
Patent and Trademark Office ( USPTO ) issued the Company its first patent
related to the design of the new Portable Neuromodulation Stimulation ( PoNS )
4.0 device. The PoNS is currently being studied in the United States for the
treatment of chronic balance symptoms caused by mild-moderate Traumatic Brain
Injury ( TBI ) and in Canada for chronic balance and gait symptoms caused by
U.S. Patent No. 9,072,889, Systems for Providing Non-Invasive
Neurorehabilitation of a Patient , issued on July 7, 2015, is the first of
several design and utility patents to issue related to the new PoNS design.
This is the fourth U.S. patent Helius has received related to the PoNS
technology platform, and the first related specifically to the new device
We are excited to see the first patent issued for the new
PoNS design, a strong addition to our existing portfolio, said Philippe
Deschamps, Chief Executive Officer of Helius. We will continue to aggressively
develop our intellectual property position in this unique technology space.
The PoNSTM device is a non-invasive means for
delivering neurostimulation through the tongue. Researchers believe that use of
the tongue as a gateway to the brain may be one of the most natural,
non-invasive and direct ways to stimulate the brain. The tongue is anatomically
unique, being richly innervated by thousands of nerve fibers and interconnected
to the brainstem by two major cranial nerves.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company
focused on neurological wellness. The company seeks to develop, license and
acquire unique non-invasive treatments designed to amplify the brain s ability
to heal itself. Helius intends to file for U.S. Food and Drug Administration
clearance for the PoNS device. For more information, please visit
www.heliusmedical.com. The contents of this website are not, and should not be
deemed to be, incorporated by reference herein.
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does
not accept responsibility for the adequacy or accuracy of the content of this
All statements in this news release, other than statements
of historical facts, are forward-looking statements. Forward-looking statements
are often identified by terms such as will , may , should , anticipate ,
expects and similar expressions. All statements other than statements of
historical fact included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements
will prove to be accurate and actual results and future events could differ
materially from those anticipated in such statements. Important factors that
could cause actual results to differ materially from the Company s expectations
include the failure to satisfy the conditions of the Securities and Exchange
Commission and the Canadian Securities Exchange, the success of the Company s
business plan, availability of funds, government regulations, operating costs, the Company s
ability to achieve revenues and other risks detailed from time to time in the
filings made by the Company with its securities regulators.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be incorrect. Events
or circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company. The reader
is cautioned not to place undue reliance on any forward-looking information.
Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially
from those anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made as of the
date of this news release and the Company assumes no obligation to update the
forward-looking statements except as required by applicable law.
Canadian Investor Relations: